Global Pet Cancer Therapeutics Market Revenue Estimated Around USD 12.06 Billion By 2034

According to the report, the global pet cancer therapeutics market size was valued at approximately USD 4.78 billion in 2024 and is predicted to reach around USD 12.06 billion by the end of 2034, expanding at a CAGR of around 9.7% from 2025 to 2034.

The growth of the global pet cancer therapeutics market is anticipated to boost owing to the rising incidence of numerous cancer types in dogs and cats, along with the rise in R&D initiatives in relation to cancer management in animals. Further, the rising pet health alertness is also projected to spur the growth of the market soon.

To cite, a research grant was received in 2017 by the Animal Cancer Foundation (ACF) from the Blue Buffalo Foundation of US$ 1 million to shore up oncology research that aimed at examining the resemblance between naturally occurring cancers in pets & people and looking for helpful management in both species. Nevertheless, side effects owing to the drugs utilized for treating pet cancers and the disinclination of pet owners to make their pet animals undergo medication are likely to hamper the growth of the pet cancer therapeutics market in the coming period.

The global pet cancer therapeutics market is segmented based on therapy type, species, cancer type, end-user, and region.

Lymphoma Segment Of The Market Likely To Hold The Highest Shares During The Forecast Period

Based on Therapy Type, the global pet cancer therapeutics market is divided into chemotherapy, targeted therapy, immunotherapy, and radiation therapy. On the basis of Species, the global pet cancer therapeutics market is bifurcated into dogs, cats, and others. By Cancer Type, the global pet cancer therapeutics market is split into lymphoma, Mast cell cancer, melanoma, mammary & skin cancer, and others. In terms of End-user, the global pet cancer therapeutics market is categorized into veterinary hospitals, veterinary clinics, and research institutes.

Deep-Rooted Healthcare Infrastructure To Help North America Dominate The Market

The global pet cancer therapeutics market is expected to be ruled by North America and followed by Europe. The market growth in these regions can be attributed to the existence of prominent players, entrenched healthcare infrastructure, rise in prevalence & incidence of pet cancer, and a rise in R&D spending. Further, the Asia Pacific market for pet cancer therapeutics is anticipated to witness substantial growth in the near future. The growth is projected to be propelled by China and India, on account of rising prevalence & incidence of pet cancer, increasing disposable income, mounting government initiatives, increasing alertness, and thriving veterinary infrastructure.

Browse the full “Pet Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy), By Species (Dogs, Cats, and Others), By Cancer Type (Lymphoma, Mast Cell Cancer, Melanoma, Mammary & Skin Cancer, and Others), By End-user (Veterinary Hospitals, Veterinary Clinics, and Research Institutes), and By Region: Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034” Report at https://www.zionmarketresearch.com/report/pet-cancer-therapeutics-market

The active players in the global pet cancer therapeutics market consist of Karyopharm Therapeutics Inc., Zoetis, Oasmia Pharmaceuticals AB, Zenoaq, AB Science, Aratana Therapeutics Inc., Rhizen Pharmaceuticals SA, Morphogenesis Inc., Boehringer Ingelheim International GmbH, Regeneus Ltd., VetDC Inc., and others.

The global pet cancer therapeutics market is segmented as follows:

By Therapy Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy

By Species

• Dogs
• Cats
• Others

By Cancer Type

• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary & Skin Cancer
• Others

By End-user

• Veterinary Hospitals
• Veterinary Clinics
• Research Institutes

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com